Servi­er bags an an­ti­body spe­cial­ist in its lat­est on­col­o­gy M&A deal with plans to add the plat­form tech

What­ev­er Servi­er learned about Sym­phogen dur­ing their 2-year de­vel­op­ment al­liance must have sig­nif­i­cant­ly whet­ted their ap­petite for an ac­qui­si­tion.

Paris-based Servi­er an­nounced Fri­day that it …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER